

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

May 20, 2024

To Shareholders,

Company Name: Renascience Inc.
Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

**Notice of Conclusion of License Agreement with HI-LEX Medical
for Disposable Ultrafine Endoscope**

The Company has terminated the license agreement with Baxter Helthcare Corporation (hereinafter referred to as "Baxter") for the disposable ultrafine endoscope (hereinafter referred to as "Device") and has entered into a new license agreement (hereinafter referred to as "Agreement") with HI-LEX Medical (hereinafter referred to as "HI-LEX") for the Device.

1. Background of the Agreement

In May 2020, the Company entered into a license agreement with Baxter for the co-development and commercialization of the Device, which enables non-invasive peritoneal observation in peritoneal dialysis therapy. In December 2022, the Ministry of Health, Labour and Welfare approved the fiberscope, the main component of the Device, for the medical use, and Baxter planned to commercialize the fiberscope. However, Baxter has decided to withdraw from the business of the Device, and the Company has terminated the license agreement with Baxter.

The Company entered into a collaboration agreement with HI-LEX and its parent company, HI-LEX Corporation, in September 2022 regarding the development of medical devices, including the creation of a guide catheter as an accessory component to the Device, and has been working closely with HI-LEX and HI-LEX Corporation as business partners. HI-LEX has expressed interest in the commercialization of the Device, and the Agreement is executed today. HI-LEX will commercialize the Device with the aim of filing regulatory approval as soon as possible. In addition to peritoneal dialysis therapy, the Company and HI-LEX plan to jointly maximize the value of the Device by commercializing it for other medical applications.

2. Impact on business performance of the Company

The Company expects to receive the payment under the Agreement from HI-LEX in the future depending on the stage of development, and also the royalty after commercialization. The payment under the Agreement can be approximately 20% of the projected revenue for the current fiscal year.

3. Outline of the licensee

(1)	name	HI-LEX Medical
(2)	Location	6F Crobis Kinshicho, 4-24-3 Koto-bashi, Sumida-ku, Tokyo

(3)	Title and name of representative	President & Representative Director: Taro Teraura	
(4)	Business	<ul style="list-style-type: none"> • Import and sales of medical equipment • Repair and maintenance of medical equipment • Support services related to healthcare (including research and provision of information, management, logistics, establishment of facilities) • Support services for medical device development (identifying seeds and providing needs) 	
(5)	Capital stock	100 million yen	
(6)	Date of Establishment	August 30, 2021	
(7)	Major Shareholders and Shareholding Ratio (As of September 30, 2023)	HI-LEX Corporation 100%.	
(8)	The relationship with the Company	Capital ties	None
		Personal relations	None
		Business relations	Executed of a collaboration agreement on the development of medical devices including artificial intelligence (AI) on September 1, 2022.
		Status of related party	None

End